Myriad Genetics, a prominent company specialising in genetic testing and precision medicine, has recently announced that it has been granted a patent by the U.S. Patent and Trademark Office for its ground-breaking blood collection device used in fetal sex determination tests. The patent, with the identification number 11,932,907, offers protection for the use of push-button blood collection devices specifically for PCR-based fetal sex determination, particularly for the company’s SneakPeek Snap products in the United States until 2040.
This patented technology aims to improve the accuracy of fetal sex testing by reducing the presence of contaminating DNA in maternal blood samples. The blood collection method simplifies the process of obtaining a sample at home, making the task as simple as placing the device on the arm and pressing a button, with the sample collection completed in one to four minutes.
Clinical studies have demonstrated that the SneakPeek Snap device significantly reduces the risk of contamination from external male DNA in maternal blood samples, ensuring a high level of accuracy in determining fetal sex.
Dr. Dale Muzzey, Chief Scientific Officer at Myriad Genetics, expressed that the patent recognises the company’s innovative approach to fetal sex testing using PCR-based techniques with any push-button blood collection device. The patent not only strengthens SneakPeek Snap’s exclusivity in the U.S. market but also opens up opportunities for potential licensing deals with leading suppliers in the field, positioning Myriad Genetics as a strategic partner.
Myriad Genetics offers a range of genetic tests that help in evaluating disease risk, monitoring disease progression, and informing treatment decisions across various medical specialties, with the aim of enhancing patient care and reducing healthcare costs.
The company’s forward-looking statement in the press release indicates an expectation that the SneakPeek Snap patent will protect its products through 2040 and may lead to licensing opportunities with key push-button blood collection device suppliers. However, Myriad also notes that these expectations are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated.
It is important to note that this article is based on a press release statement from Myriad Genetics.
In conclusion, the recent patent secured by Myriad Genetics for its innovative fetal sex test technology marks a significant milestone for the company. The technology not only enhances the accuracy of fetal sex testing, but also positions Myriad Genetics at the forefront of the genetic testing and precision medicine industry. With this patent, the company is poised to forge strategic partnerships and pave the way for continued advancements in genetic testing and precision medicine.
+ There are no comments
Add yours